Cargando…
Clinical Characteristics and Outcomes of Patients With Mpox Who Received Tecovirimat in a New York City Health System
BACKGROUND: The 2022 global mpox outbreak was notable for transmission between persons outside of travel and zoonotic exposures and primarily through intimate contact. An understanding of the presentation of mpox in people with human immunodeficiency virus (HIV) and other immunocompromising conditio...
Autores principales: | Vo, Christopher, Zomorodi, Rustin, Silvera, Richard, Bartram, Logan, Lugo, Luz Amarilis, Kojic, Erna, Urbina, Antonio, Aberg, Judith, Sigel, Keith, Chasan, Rachel, Patel, Gopi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10644828/ https://www.ncbi.nlm.nih.gov/pubmed/38023539 http://dx.doi.org/10.1093/ofid/ofad552 |
Ejemplares similares
-
Tecovirimat for the treatment of severe Mpox in Germany
por: Hermanussen, Lennart, et al.
Publicado: (2023) -
Racial and Socioeconomic Equity of Tecovirimat Treatment during the 2022 Mpox Emergency, New York, New York, USA
por: Lash, Maura K., et al.
Publicado: (2023) -
Tecovirimat Resistance in Mpox Patients, United States, 2022–2023
por: Smith, Todd G., et al.
Publicado: (2023) -
2684. Characteristics of mpox patients treated with Tecovirimat: a single center review
por: Vargas, Robert, et al.
Publicado: (2023) -
Treatment of Mpox with Suspected Tecovirimat Resistance in Immunocompromised Patient, United States, 2022
por: Contag, Caitlin A., et al.
Publicado: (2023)